EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting genomic instability in cancer

Timothy A Yap, H Charles Manning, Puja Sapra, Gordon B Mills, Mark J O'Connor

Cell · 2026-04 · 189 (8) · 2278-2306

DOI: 10.1016/j.cell.2026.03.035 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell, 2026-04. Verfasst von Timothy A Yap und 4 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutics Discovery Division, Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX, U…. Hauptthemen laut MEDLINE: Genomic Instability, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 222 Literaturangaben. Gefördert von: National Institutes of Health, Cancer Prevention and Research Institute of Texas, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic instability is a defining feature of cancer, which arises when the cellular systems that maintain DNA integrity falter, enabling the accumulation of genetic and epigenetic alterations that drive malignant transformation. It is both the architect of cancer's evolution and its Achilles' heel. Targeting genomic instability has reshaped oncology: first through systemic chemotherapy and external beam radiation and then with poly(ADP-ribose) polymerase (PARP) inhibitors in homologous recombination repair-deficient tumors and other DNA damage response targets. Recently, tumor-targeted DNA-damaging platforms, namely antibody-drug conjugates (ADCs) and radiopharmaceuticals, have emerged alongside modern precision medicine strategies to optimize patient selection, develop rational combinations, and widen the therapeutic index.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genomic InstabilityNeoplasmsHumansAnimalsPoly(ADP-ribose) Polymerase InhibitorsDNA DamageAntineoplastic AgentsImmunoconjugates

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsImmunoconjugates

Autor:innen und Institutionen

  • Therapeutics Discovery Division, Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: tyap@mdanderson.org.
  • Department of Nuclear Medicine, Diagnostic Imaging Division, RADIATE Theranostics R&D Platform, Therapeutics Discovery Division, Cyclotron Radiochemistry Facility, University of Texas MD Anderson Cancer Center, Houston,…
  • Biologics Engineering & Oncology Targeted Discovery, AstraZeneca, Gaithersburg, MD, USA.
  • Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Oncology R&D, AstraZeneca, Cambridge, UK. Electronic address: mark.j.oconnor@astrazeneca.com.

Förderung

  • National Institutes of Health
  • Cancer Prevention and Research Institute of Texas
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • National Cancer Center
  • University of Texas MD Anderson Cancer Center
  • U.S. Department of Defense
  • Colorectal Cancer Alliance
  • National Cancer Institute

Zitieren

APA

Yap, T. A., Manning, H. C., Sapra, P., Mills, G. B., & O'Connor, M. J. (2026). Targeting genomic instability in cancer. Cell, 189(8), 2278-2306. https://doi.org/10.1016/j.cell.2026.03.035

Vancouver

Yap TA, Manning HC, Sapra P, Mills GB, O'Connor MJ. Targeting genomic instability in cancer. Cell. 2026;189(8):2278-2306. doi:10.1016/j.cell.2026.03.035

BibTeX
@article{Yap2026,
  author = {Yap, Timothy A and Manning, H Charles and Sapra, Puja and Mills, Gordon B and O'Connor, Mark J},
  title = {Targeting genomic instability in cancer},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {8},
  pages = {2278--2306},
  doi = {10.1016/j.cell.2026.03.035}
}
Kostenlos starten →